Fischer Medical Ventures Logs Robust 186% Growth in Total Income During FY26
Fischer Medical Ventures Limited, a prominent player in laboratory-grade chemical processing, manufacturing, and trading, has unveiled its audited financial performance for the fiscal year ended March 2026, showcasing exceptional growth across key metrics.
Financial Performance Surge
The company's consolidated revenue climbed 179% year-on-year to ₹30,857.56 crore in FY26, up from ₹11,069.87 crore in the preceding year. Total income expanded even more sharply, rising 186% to ₹32,088.93 crore compared to ₹11,219.07 crore previously.
The earnings before interest, tax, depreciation, and amortization (EBITDA) demonstrated particularly striking growth, jumping over tenfold to ₹5,539.71 crore from ₹480.88 crore, with margins expanding by 1,300 basis points to reach 17.3%. Net profitability climbed dramatically by 2,489% to ₹3,107.38 crore from ₹120.02 crore, while net profit margins improved by 860 basis points to 9.7%.
The first half of FY26 also delivered robust performance, with total income reaching ₹20,119.15 crore, a 227% increase from ₹6,144.95 crore in the corresponding period of FY25.
Leadership Commentary
Ravindran Govindan, Chairman of Fischer Medical Ventures, attributed the strong performance to operational scaling and enhanced product realization. "FY26 was a very strong year for Fischer, marking significant improvement across all operational and financial parameters. The steep rise in profitability reflects the scalability of our model, better product realization, and the growing acceptance of Fischer's technology across India and overseas markets," he stated.
Govindan highlighted the company's alignment with broader industry trends, noting that India's medical technology and diagnostic sector is expanding rapidly due to government emphasis on domestic manufacturing, preventive healthcare, and artificial intelligence-driven solutions. Fischer is leveraging its capabilities in MRI systems, AI diagnostics, and digital health platforms to strengthen its competitive position.
Operational Milestones
The fiscal year witnessed several significant business developments. Fischer launched new X-ray projects across India and Indonesia, including a partnership with the City of Jember to deploy AI-enabled portable X-ray systems supporting TB elimination initiatives valued at approximately USD 10 million. The company secured full licensing in Indonesia and received an order from the Tamil Nadu Animal Husbandry Department for 65 Digital Radiography Units.
In the Philippines, the Province of Bulacan inaugurated the nation's first locally funded MRI facility developed through Fischer's subsidiary Time Medical. Within India, the company installed high-resolution open MRI systems at multiple facilities in Chennai and Sikkim, and launched new MRI platforms including a low-field TOF system designed specifically for brain aneurysm imaging.
Fischer also unveiled next-generation 1.5T MRI platforms at IRIA 2026 and developed the DRIS-iMRI Medharanya, an intraoperative MRI system created in collaboration with Dr. Iype Cherian to provide real-time visualization during complex neurosurgical procedures.
The company achieved recognition as an Industry Partner of the World Federation of Neurosurgical Societies' Innovation and Technological Committee, marking the first instance of such recognition in the organization's history.
Additionally, Fischer's Nanomedic division completed Phase 1 of its Medical Device Regulation and Medical Device Directive audit, with Phase 2 scheduled for October 2025. The division is preparing FDA filings for its SpinCare® product, with results anticipated in the second quarter of FY27.
Management expressed confidence in maintaining growth momentum, citing its expanding footprint across Southeast Asia and upcoming product innovations as drivers of long-term value creation.
Compare options


